Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272817 · ClinicalTrials.gov registry record · NA
Nonmyeloablative Allogeneic Transplant
A NA study, sponsored by Scripps Health.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT01272817: Completed NA study, sponsored by Scripps Health.
NCT01272817 is a NA study that has completed, run by Scripps Health. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272817, a NA study, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.
Primary Outcome
Evaluation of engraftment of donor stem cells by bone marrow examinations at days 30, 100, and 360 after transplant.
Interventions
- PROCEDURE Nonmyeloablative Allogeneic Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2001-10 |
| Est. Completion | 2015-10 |
| Phase | NA |
What the finished NCT01272817 record still lists
NCT01272817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Nonmyeloablative Allogeneic Transplant is the first listed.
NCT01272817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01272817 about?
NCT01272817 is a clinical study titled "Nonmyeloablative Allogeneic Transplant". Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.
What is the current status of trial NCT01272817?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2001-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01272817?
The interventions under investigation include: Nonmyeloablative Allogeneic Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT01272817?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01272817's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia